Health and Human Services Sector
Issues seen with drugs to curb prostate cancer: FDA
Nov 29, 2010 12:48 EST
WASHINGTON (Reuters) - U.S. regulatory staff have raised concerns about data for two drugs by GlaxoSmithKline Plc and Merck & Co Inc and their effect on reducing the risk of prostate cancer in certain men.
FDA reviews 2 new drugs to reduce prostate cancer
Nov 29, 2010 12:22 EST
Health regulators said Monday that two drugs from GlaxoSmithKline and Merck reduce the risk of prostate cancer in men, though scientists questioned the drugs' overall benefit, since the tumors they prevent are usually not life-threatening.
FDA reviews 2 new drugs to reduce prostate cancer
Nov 29, 2010 12:22 EST
FDA considers broader approval of Glaxo, Merck prostate drugs shown to reduce tumor risks. Health regulators said Monday that two drugs from GlaxoSmithKline and Merck reduce the risk of prostate cancer in men, though scientists questioned the drugs' overall benefit, since the tumors they prevent are usually not life-threatening.
Congress GOP leaders to meet with governors
Nov 29, 2010 12:07 EST
Congressional GOP leaders to meet with Republican governors Wednesday. Top Republicans in Congress are meeting with more than a dozen GOP governors this week to discuss spending cuts, job creation and repealing President Barack Obama's health care law.
FDA reviews 2 new drugs to reduce prostate cancer
Nov 29, 2010 09:34 EST
FDA considers broader approval of Glaxo, Merck prostate drugs shown to reduce tumor risks. Health regulators say two drugs from GlaxoSmithKline and Merck reduce the risk of prostate tumors in men, though scientists complain the companies only studied a small number of African Americans, who are at high risk for prostate cancer.
Austere times demand healthcare efficiency: OECD
Nov 29, 2010 07:46 EST
LONDON (Reuters) - Cash-strapped governments can no longer raise spending to improve healthcare at the breakneck pace of recent decades, so they must make systems more efficient to offer quality care at no extra cost, the OECD said Monday.
J&J must pay Basilea $130 million for drug license breach
Nov 29, 2010 07:01 EST
ZURICH (Reuters) - Johnson & Johnson <JNJ.N> must pay former Swiss partner Basilea <BSLN.S> about $130 million for breaching a license agreement for a superbug antibiotic, a Dutch arbitration tribunal has ruled.
Analysis: Pharma's woes not over, more restructuring seen
Nov 28, 2010 11:22 EST
NEW YORK (Reuters) - Global drugmakers have cut tens of thousands of jobs ahead of patent expirations on their top-selling products, and the pain is not yet over.
Hedge fund FrontPoint hit by $3 billion in redemptions
Nov 26, 2010 15:22 EST
BOSTON (Reuters) - FrontPoint Partners, a $7.5 billion hedge fund currently embroiled in the U.S. government's fast-moving insider trading probe, has been asked to return $3 billion to its investors.
Vaccine alliance says 5-in-1 vaccine cost to fall
Nov 26, 2010 12:37 EST
LONDON (Reuters) - The price of a life-saving vaccine against five deadly diseases is expected to drop further in 2011, allowing more of the world's poorest children to be immunized, the global vaccines group GAVI said on Friday.
Bad blood grows between Swiss drug CEOs
Nov 26, 2010 11:11 EST
ZURICH (Reuters) - Relations have turned icy between the CEOs of Roche and Novartis as Switzerland's top two drug executives defend their very different strategies to making money in a tough healthcare market.
Genzyme open to Campath clause in Sanofi bid: report
Nov 26, 2010 05:33 EST
PARIS (Reuters) - Genzyme <GENZ.O>, resisting a hostile bid from Sanofi-Aventis <SASY.PA>, is open to a deal that links its value to the success of key drug Campath, the U.S. biotech's chief executive was quoted as saying.
APNewsBreak: Nev. court backs hormone drug verdict
Nov 24, 2010 17:07 EST
APNewsBreak: Nevada Supreme Court upholds $58M judgment against Wyeth over hormone drugs. The Nevada Supreme Court on Wednesday upheld a $58 million award to three women who claimed their breast cancer was caused by hormone replacement drugs made by Wyeth Pharmaceuticals.
APNewsBreak: Nev. court backs hormone drug verdict
Nov 24, 2010 17:07 EST
The Nevada Supreme Court on Wednesday upheld a $58 million award to three women who claimed their breast cancer was caused by hormone replacement drugs made by Wyeth Pharmaceuticals.
Health activists try to attract dentists to rural areas
Nov 24, 2010 15:16 EST
KANSAS CITY, Kansas (Reuters) - It's a sacrifice some people make by living in the wide-open spaces: nobody to take care of their teeth.
APNewsBreak: NV court upholds award against Wyeth
Nov 24, 2010 14:27 EST
APNewsBreak: NV Supreme Court upholds judgment against drug maker. The Nevada Supreme Court has upheld a $58 million judgment awarded to three women who claimed their breast cancer was caused by hormone replacement drugs made by Wyeth Pharmaceuticals.
APNewsBreak: NV court upholds award against Wyeth
Nov 24, 2010 14:26 EST
APNewsBreak: NV Supreme Court upholds judgment against drug maker. The Nevada Supreme Court has upheld a $58 million judgment awarded to three women who claimed their breast cancer was caused by hormone replacement drugs made by Wyeth Pharmaceuticals.
US gives funds to Zambia to fight AIDS
Nov 24, 2010 11:21 EST
Zambia is to receive 276 million dollars (206 euros) from the US government to help battle HIV and AIDS, officials said Tuesday.
Genzyme meets first consent decree deadline
Nov 24, 2010 11:16 EST
BOSTON (Reuters) - Genzyme Corp <GENZ.O> has met the first in a series of deadlines imposed by U.S. regulators for fixing problems at its Boston plant, a milestone that could bolster the biotech company's argument that it is worth more than the $18.5 billion being offered by French drugmaker Sanofi-Aventis SA <SASY.PA>.
Germany's top court upholds restrictive GM crops law
Nov 24, 2010 09:22 EST
Germany's top court on Wednesday upheld a two-year-old law placing sharp restrictions on the use of genetically modified crops, saying it protected the public from the risks of the technology.
